Agilent Announces Genohm Acquisition
Agilent Technologies has announced an agreement to acquire Genohm, a developer of highly differentiated, on-premise, and cloud-based software solutions for laboratory management.
Agilent Technologies (Santa Clara, California, USA) has announced an agreement to acquire Genohm (Lausanne, Switzerland), a developer of highly differentiated, on-premise, and cloud-based software solutions for laboratory management.
Genohm’s main laboratory software automation suite, SLIMS, is a digital platform that provides laboratories with a rapidly deployable laboratory information management system (LIMS) and electronic lab notebook (ELN) environment that is used in biobanks, research labs, and next generation sequencing facilities. The platform tracks data and samples, tests and users, results, and workflows. In addition, Genohm also has an application marketplace with preconfigured workflows to enable rapid system implementation across a broad range of industries and scientific workflows.
“We were impressed with the team and the technology,” said John Sadler, Vice President and General Manager of Agilent’s Software and Informatics Division. “The modern architecture of SLIMS is perfectly aligned with the values of Agilent’s OpenLab products. By integrating this technology with our broad and diverse instrument portfolio, we are in a unique position to support and enhance the operations of modern laboratories-truly helping our customers to do more with their data.”
“We are very excited to join the Agilent team and believe that together we can accelerate development of the digital lab to help our customers advance science and discovery while ensuring compliance and traceability,” said Frederik Decouttere, founder and CEO of Genohm.
For more information, please visit: www.agilent.com or www.genohm.com
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
